Home Other Building Blocks 2-Chloroadenine

2-Chloroadenine

CAS No.:
1839-18-5
Catalog Number:
AG003391
Molecular Formula:
C5H4ClN5
Molecular Weight:
169.5718
Pack Size
Purity
Availability
Location
Price(USD)
Quantity
  
1g
96%
In Stock USA
United States
$13
- +
5g
96%
In Stock USA
United States
$57
- +
10g
96%
In Stock USA
United States
$94
- +
25g
96%
In Stock USA
United States
$169
- +
100g
96%
In Stock USA
United States
$513
- +
Product Description
Catalog Number:
AG003391
Chemical Name:
2-Chloroadenine
CAS Number:
1839-18-5
Molecular Formula:
C5H4ClN5
Molecular Weight:
169.5718
MDL Number:
MFCD00037925
IUPAC Name:
2-chloro-7H-purin-6-amine
InChI:
InChI=1S/C5H4ClN5/c6-5-10-3(7)2-4(11-5)9-1-8-2/h1H,(H3,7,8,9,10,11)
InChI Key:
HBJGQJWNMZDFKL-UHFFFAOYSA-N
SMILES:
Clc1nc(N)c2c(n1)nc[nH]2
NSC Number:
7362
Properties
Complexity:
154  
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
1  
Defined Atom Stereocenter Count:
0
Defined Bond Stereocenter Count:
0
Exact Mass:
169.016g/mol
Formal Charge:
0
Heavy Atom Count:
11  
Hydrogen Bond Acceptor Count:
4  
Hydrogen Bond Donor Count:
2  
Isotope Atom Count:
0
Molecular Weight:
169.572g/mol
Monoisotopic Mass:
169.016g/mol
Rotatable Bond Count:
0
Topological Polar Surface Area:
80.5A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
XLogP3:
0.4  
Literature
Title Journal
Correlation of the time course of development and decay of tolerance to morphine with alterations in sodium pump protein isoform abundance. Biochemical pharmacology 20100401
Rofecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor increases pentylenetetrazol seizure threshold in mice: possible involvement of adenosinergic mechanism. Epilepsy research 20080101
[Synthesis of 2-chloro-2'-deoxyadenosine by microbiological transglycosylation using a recombinant Escherichia coli strain]. Prikladnaia biokhimiia i mikrobiologiia 20080101
New 2,6,9-trisubstituted adenines as adenosine receptor antagonists: a preliminary SAR profile. Purinergic signalling 20070901
Age-related changes in ischemic tolerance in male and female mouse hearts. Journal of molecular and cellular cardiology 20050201
Application of population pharmacokinetics to cladribine. BMC pharmacology 20050101
Kinetic model of oxidation catalyzed by xanthine oxidase-the final enzyme in degradation of purine nucleosides and nucleotides. Nucleosides, nucleotides & nucleic acids 20050101
Human DNA primase uses Watson-Crick hydrogen bonds to distinguish between correct and incorrect nucleoside triphosphates. Biochemistry 20040928
Cytotoxicity and pharmacokinetics of cladribine metabolite, 2-chloroadenine in patients with leukemia. Cancer letters 20040716
Determination of the deoxycytidine kinase activity in cell homogenates with a non-radiochemical assay using reversed-phase high performance liquid chromatography; Identification of a novel metabolite of 2-chlorodeoxyadenosine. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20040615
Synthesis of base substituted 2-hydroxy-3-(purin-9-yl)-propanoic acids and 4-(purin-9-yl)-3-butenoic acids. Nucleosides, nucleotides & nucleic acids 20031201
Oligonucleotides incorporating 8-aza-7-deazapurines: synthesis and base pairing of nucleosides with nitrogen-8 as a glycosylation position. Organic & biomolecular chemistry 20030607
3'-deoxyribofuranose derivatives of 1-deaza and 3-deaza-adenosine and their activity as adenosine deaminase inhibitors. Nucleosides, nucleotides & nucleic acids 20010101
Structure-activity relationships for the binding of ligands to xanthine or guanine phosphoribosyl-transferase from Toxoplasma gondii. Biochemical pharmacology 19951109
Properties